Die adjuvante Chemotherapie des Zervixkarzinoms - Ergebnisse einer Phase II-Studie

Blohmer, Jens U.; Paepke, S.; Böhmer, Daniel; Ernhardt, B.; Sehouli, Jalid; Elling, D; Lichtenegger, W.

doi:10.1055/s-2001-14788

Cited by 14 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proposed that these hormones may act via their nuclear receptors to in¯uence proto-oncogene expression (Franklyn and Sheppard, 1989). E 2 -like eects of T 3 have been observed in a variety of experimental systems, including the in¯uence of these hormones in the healthy tissues or breast cancer cells (Franklyn and Sheppard, 1989;Shao et al, 1995;Blohmer et al, 1999;Parhar et al, 2000;Qi et al, 1997;Dellovade et al, 1999Dellovade et al, , 2000Morgan et al, 2000;Barrera-Hernandez et al, 1999). Thyroid hormone-induced cell proliferation in rat pituitary GC cells has been reported to be mediated by cyclin/cyclin-dependent kinase (CDK) activity (Barrera-Hernandez et al, 1999).…”

mentioning

confidence: 99%

Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells

2002

View full text Add to dashboard Cite

T47D cells represent an estrogen-responsive human ductal carcinoma cell line which expresses detectable levels of estrogen receptor (ER). We have previously shown that estradiol (E 2 ) treatment of T47D cells causes an increase in the level of p53 and a concomitant phosphorylation of retinoblastoma protein (pRb). In the present study, we have analysed the expression of p53 and phosphorylation state of pRb and compared the eects of E 2 and triiodothyronine (T 3 ) on these phenomena. Cells were grown in a medium containing charcoal-treated serum to deplete the levels of endogenous steroids. Upon con¯uency, the cells were treated with T 3 (10 712 to 10 77 M) for 24 h and the presence of p53 and pRb was detected by Western analysis. E 2 treatment of cells caused a 2 ± 3-fold increase in the level of p53. Presence of T 3 in the medium caused a gradual increase in the level of p53 in a concentration-dependent manner. Under the above conditions, pRb was phosphorylated (detected as an upshift during SDS ± PAGE) in the presence of E 2 and T 3 . Supplementation of growth medium with T 3 (1 mM) caused an increase in the rate of proliferation of T47D cells and induced hyperphosphorylation of pRb within 4 h; this eect was maintained for up to 12 h. When ICI 164 384 (ICI) (1 mM), an ER antagonist, was combined with E 2 (1 nM) or T 3 (1 mM), eects of hormones on cell proliferation and hyperphosphorylation of pRb were blocked. Western analysis of p53 was supplemented with its cytolocalization by immuno-labeling using laser scanning confocal uorescence microscopy, which revealed an ICI-sensitive increase in the abundance of p53 in hormone-treated cells. Steroid binding analysis revealed lack of competition by T 3 for the [ 3 H]E 2 binding. These results indicate that T 3 regulates T47D cell cycle progression and proliferation raising the p53 level and causing hyperphosphorylation of pRb by a common mechanism involving ER and T 3 receptor (T 3 R)-mediated pathways.

show abstract

mentioning

confidence: 99%

Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells

2002

View full text Add to dashboard Cite

show abstract

“…The chemotherapeutic regimen of the intervention group did not include cisplatin in five studies (Blohmer 2001; Kato 1994;Lahousen 1999; Richter 1982; Yamamoto 2004). Two studies evaluated chemotherapy (and not radiotherapy) in the control arm (Curtin 1996; Lahousen 1999).…”

Section: Resultsmentioning

confidence: 99%

Adjuvant platinum-based chemotherapy for early stage cervical cancer

Rosa

Medeiros

Edelweiss

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background This is an updated version of the original Cochrane review published in The Cochrane Library 2009, Issue 3. Most women with early cervical cancer (stages I to IIA) are cured with surgery or radiotherapy, or both. We performed this review originally because it was unclear whether cisplatin-based chemotherapy after surgery, radiotherapy or both, in women with early stage disease with risk factors for recurrence, was associated with additional survival benefits or risks. Objectives To evaluate the effectiveness and safety of platinum-based chemotherapy after radical hysterectomy, radiotherapy, or both in the treatment of early stage cervical cancer. Search methods For the original 2009 review, we searched the Cochrane Gynaecological Cancer Group Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2009, Issue 1), MEDLINE, EMBASE, LILACS, BIOLOGICAL ABSTRACTS and CancerLit, the National Research Register and Clinical Trials register, with no language restriction. We handsearched abstracts of scientific meetings and other relevant publications. We extended the database searches to November 2011 for this update. Selection criteria Randomised controlled trials (RCTs) comparing adjuvant cisplatin-based chemotherapy (after radical surgery, radiotherapy or both) with no adjuvant chemotherapy, in women with early stage cervical cancer (stage IA2-IIA) with at least one risk factor for recurrence. Data collection and analysis Two review authors extracted data independently. Meta-analysis was performed using a random-effects model, with death and disease progression as outcomes. Main results For this updated version, we identified three additional ongoing trials but no new studies for inclusion. Three trials including 368 evaluable women with early cervical cancer were included in the meta-analyses. The median follow-up period in these trials ranged from 29 to 42 months. All women had undergone surgery first. Two trials compared chemotherapy combined with radiotherapy to radiotherapy alone; and one trial compared chemotherapy followed by radiotherapy to radiotherapy alone. It was not possible to perform subgroup analyses by stage or tumour size. Compared with adjuvant radiotherapy, chemotherapy combined with radiotherapy significantly reduced the risk of death (two trials, 297 women; hazard ratio (HR) = 0.56, 95% confidence interval (CI): 0.36 to 0.87) and disease progression (two trials, 297 women; HR = 0.47, 95% CI 0.30 to 0.74), with no heterogeneity between trials (I2 = 0% for both meta-analyses). Acute grade 4 toxicity occurred significantly more frequently in the chemotherapy plus radiotherapy group than in the radiotherapy group (risk ratio (RR) 5.66, 95% CI 2.14 to 14.98). We considered this evidence to be of a moderate quality due to small numbers and limited follow-up in the included studies. In addition, it was not possible to separate data for bulky early stage disease. In the one small trial that compared adjuvant chemotherapy followed by radio...

show abstract

Adjuvant platinum-based chemotherapy for early stage cervical cancer

Falcetta

Medeiros

Edelweiss

et al. 2009

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background-This is an updated version of the original Cochrane review published in The Cochrane Library 2009, Issue 3. Most women with early cervical cancer (stages I to IIA) are cured with surgery or radiotherapy, or both. We performed this review originally because it was unclear whether cisplatin-based chemotherapy after surgery, radiotherapy or both, in women with early stage disease with risk factors for recurrence, was associated with additional survival benefits or risks.

show abstract

Die adjuvante Chemotherapie des Zervixkarzinoms - Ergebnisse einer Phase II-Studie

Cited by 14 publications

References 11 publications

Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells

Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells

Adjuvant platinum-based chemotherapy for early stage cervical cancer

Adjuvant platinum-based chemotherapy for early stage cervical cancer

Contact Info

Product

Resources

About